In Q2 fiscal 2026 (the quarter ended June 30, 2026), Globus Medical's largest product or service was Musculoskeletal Solutions, with $763.54 million or 97% of revenue, up 7.5% from a year earlier. Next: Enabling Technologies (3%).
By region, United States brought in 78% and Non-US brought in 22% of revenue in Q2 fiscal 2026.
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.

Fiscal quarters, from company filings
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Musculoskeletal Solutions | $763.5M | $733.0M | – | $710.2M | 97% |
| Enabling Technologies | $26.1M | $26.9M | – | $35.2M | 3% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
| Region | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| United States | $619.1M | $604.9M | $617.6M | $600.8M | 78% |
| Non-US | $170.5M | $155.0M | $151.4M | $144.6M | 22% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Musculoskeletal Solutions: $763.54 million, or 97% of revenue, in Q2 fiscal 2026.
By revenue in Q2 fiscal 2026: Musculoskeletal Solutions (97%) and Enabling Technologies (3%).
By region in Q2 fiscal 2026: United States (78%) and Non-US (22%).
Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i
Fiscal quarter ended Jun 30, 2026
| Item | Revenue | Share |
|---|---|---|
| Reportable | USD 789.61M | 100.0% |
Sum of items USD 789.61M. Shares are of the items shown. Click an item with › to see its parts.
Every item and period in one grid. Purple = calculated; "–" = not available.
| Item | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Reportable | 789.6M | 759.9M | – | – | 745.3M | 598.1M | – | – |
| Musculoskeletal Solutions and Enabling Technologies | – | – | – | 769.0M | – | – | – | 625.7M |